维康药业(300878) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥115,563,051.29, a decrease of 35.34% compared to the same period last year[5] - Net profit attributable to shareholders was ¥4,729,980.10, down 87.20% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,876,303.54, a decline of 80.92% compared to the previous year[5] - Total operating revenue for Q3 2023 was CNY 432,001,715.94, a decrease of 8.93% compared to CNY 474,349,508.65 in Q3 2022[21] - Net profit attributable to shareholders of the parent company for Q3 2023 was CNY 69,350,633.99, a decline of 26.31% from CNY 93,930,944.61 in Q3 2022[23] - Earnings per share for Q3 2023 was CNY 0.4790, compared to CNY 0.6487 in Q3 2022, reflecting a decrease of 26.14%[23] - The total comprehensive income for Q3 2023 was CNY 70,873,328.94, down from CNY 94,643,387.92 in Q3 2022, reflecting a decrease of 25.14%[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,084,644,058.91, an increase of 8.93% from the end of the previous year[5] - Total assets as of September 30, 2023, amount to CNY 2,084,644,058.91, an increase from CNY 1,913,773,127.42 at the beginning of the year[18] - Total liabilities as of the end of Q3 2023 amounted to CNY 599,832,973.01, an increase of 19.43% from CNY 502,254,330.46 at the end of Q3 2022[22] - Total current liabilities increased to CNY 289,164,333.34 from CNY 257,247,305.55[18] - The company’s non-current assets total CNY 1,102,088,376.60, up from CNY 1,014,457,091.93[18] Cash Flow - The company reported a significant decrease in cash flow from operating activities, with a net cash flow of ¥26,982,615.30, down 52.67% year-on-year[12] - The net cash flow from operating activities for Q3 2023 was ¥26,982,615.30, a decrease of 52.6% compared to ¥57,006,680.59 in Q3 2022[25] - Total cash inflow from investment activities was ¥252,244,395.95, significantly higher than ¥19,927,493.00 in the same period last year[25] - The net cash flow from financing activities was ¥118,695,921.78, compared to ¥132,412,177.85 in Q3 2022, reflecting a decrease of 10.5%[25] - The total cash outflow for operating activities was ¥372,607,381.03, down from ¥404,133,194.40 in Q3 2022[25] Shareholder Information - Total number of common shareholders at the end of the reporting period is 11,850[13] - Liu Zhongliang holds 60.89% of shares, totaling 88,160,400 shares[13] - The number of shares held by the top ten shareholders represents a significant concentration of ownership, with the top shareholder alone holding over 60%[13] - Liu Zhongliang and Liu Zhongjiao, who are siblings, are the primary shareholders, indicating potential family influence in company decisions[13] Inventory and Borrowings - The company’s inventory increased by 36.83% to ¥158,871,664.81, attributed to increased stocking by subsidiaries[9] - Long-term borrowings rose by 273.10% to ¥124,589,474.13, mainly due to increased bank loans for the pharmaceutical health industry park project[9] Research and Development - Research and development expenses for Q3 2023 were CNY 19,866,229.36, a decrease of 29.38% compared to CNY 28,067,342.97 in Q3 2022[22] Investment Income - The company experienced a 245.71% increase in investment income, amounting to ¥7,203,488.32, primarily due to confirmed income from financing trade business[10] - The company reported an investment income of CNY 7,203,488.32 for Q3 2023, significantly higher than CNY 2,083,670.00 in the same period last year[22]